The results pointed out an extensive spread of infection in the five wards with seroprevalence ranging from 36

The results pointed out an extensive spread of infection in the five wards with seroprevalence ranging from 36.1% to 65.4%. 4 The Indian Council of Medical Research (ICMR) Ziyuglycoside II conducted the fourth round of national serosurvey in June-July 2021 and showed the prevalence of 67.6% among general populace. (54.6%, 95% CI: 49.7-59.4). No significant association was found between demographic or clinical factors and seropositivity. Conclusion: A high prevalence of anti-SARS-CoV-2 IgG antibodies was found among PLHIV attending ART centre indicating an exposure to the virus among them. Keywords: HIV, SARS-CoV-2, COVID-19, antibodies, seroprevalence Introduction: World Health Organization (WHO) declared novel Coronavirus Disease 2019 (COVID-19) outbreak as a pandemic and advised countries to take immediate actions on March 11, 2020. 1 India experienced a total 11,599,130 COVID-19 cases of which 2,479,682 were in Maharashtra state till March 21, 2021. 2 ?2 Table?1. Association of Anti-SARS-CoV-2 IgG Antibodies with Explanatory Variables. = 402) 1000208 (54.5)174 (45.5)382 (95.0)0.962>100011 (55.0)9 (45.0)20 (5.0) Treatment Substitution Yes194 (56.4)150 (43.6)344 (84.9)0.079No27 (44.3)34 (55.7)61 (15.1) Period on ART < 3 years23 (48.9)24 (51.1)47 (11.6)3.1- 5 years24 (54.5)20 (45.5)44 (10.9)0.6675.1 to 10 years79 (52.7)71 (47.3)150 Rabbit Polyclonal to KITH_HHV1C (37.0)>10 years95 (57.9)69 (42.1)164 (40.5) Duration of HIV Ziyuglycoside II contamination < 3 years20 (48.8)21 (51.2)41 (10.1)3.1- 5 years15 (68.2)7 (31.8)22 (5.4)5.1 to 10 years67 (52.3)61 (47.7)128 (31.6)0.467>10 years119 (55.6)95 (44.4)214 (52.8) ART regimen Zidovudine based21 (51.2)20 (48.8)41 (10.1)Tenofovir based192 (54.5)160 (45.5)352 (86.9)0.640Other8 (66.7)4 (33.3)12 (3.0) Symptoms related to COVID-19 in last 30 days Yes7 (58.3)5 (41.7)12 (3.0)0.790No214 (54.5)179 (45.5)393 (97.0) Open in a separate windows The COVID-19 positivity rate of Pune city in Maharashtra state was 16.04% on July 1, 2020 which increased to 22.10% on July 27, 2020 and was highest in the country. 3 A study conducted by scientists and epidemiologists from your Indian Institute of Science Education and Research (IISER), Pune, between 20th July and 5th August 2020 with random blood samples of 1664 persons taken by teams from five high-incidence wards in Pune city had shown prevalence of 51.5%. The results mentioned an extensive spread of contamination in the five wards with Ziyuglycoside II seroprevalence ranging from 36.1% to 65.4%. 4 The Indian Council of Medical Research (ICMR) conducted the fourth round of national serosurvey in June-July 2021 and showed the prevalence of 67.6% among general populace. It was 58% for the six districts in Maharashtra State.5,6 This disease has impacted everyone across the globe especially individuals with comorbid conditions. World Health Business mentioned that the risk of developing severe COVID-19 was 30% greater among people living with HIV (PLHIV) as compared to HIV uninfected individuals 7 and those having lower CD4 count and not taking antiretroviral treatment (ART) were at increased risk of opportunistic infections. 8 However, evidence whether PLHIV have an increased risk of acquisition of SARS-CoV-2 contamination and/or COVID-19 clinical complications is usually conflicting. 9 HIV is usually a major public health problem with 2.14 million estimated PLHIV in India. There are around 11,33,950 PLHIV on treatment under Ziyuglycoside II national program in 532 Antiretroviral Therapy (ART) centres by August 2017. 10 The seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies greatly helps in understanding the disease transmission, estimated total infections, populace susceptibility and the measures to be followed for mitigating the COVID-19 contamination. The data on susceptibility to SARS-CoV-2 infections and the risk of mortality among PLHIV is usually evolving. The purpose of this study was to determine the seroprevalence of anti-SARS-CoV-2 IgG antibodies among people living with HIV attending ART centre in Pune, India. Material and Methods: Study Design, Setting, and Participants This observational cross-sectional study was conducted in a medical center at the Indian Council of Medical Research-National AIDS Research Institute (ICMR-NARI). This outpatient medical center is affiliated to the National AIDS Control Business (NACO) and caters to a proportion of PLHIV in Pune city. HIV infected adults from March 2021 through June 2021 were included in the study. Sample size was estimated to detect 40% probability of having COVID-19 antibodies among general populace, 4 with complete precision of 5% at a 95% confidence level. A total of 405 HIV infected individuals attending ART centre regularly were selected consecutively for this observational study at the medical center. Ethical Approval and Informed Consent The study was approved by the Ziyuglycoside II ICMR-NARI Institutional Ethics Committee.